Ensuring Safety of Anticoagulation Therapy

Similar documents
Venous Thromboembolism National Hospital Inpatient Quality Measures

Treatment Options and How They Work

Incorporated Dosing Guidelines: Intravenous Heparin Therapy Initial Dose

Objectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)

HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)

Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders

DEEP VEIN THROMBOSIS (DVT): TREATMENT

2.5 Other Hematology Consult:

Heparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR

Obesity, renal failure, HIT: which anticoagulant to use?

CANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital

THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY

Venous Thromboembolism Prophylaxis

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015

10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline

WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT

Clinical Guideline for Anticoagulation in VTE

Anticoagulation

Oral Anticoagulation Drug Class Prior Authorization Protocol

SOC s Guide to the 2013 CMS New Core Measures for Stroke

Dr. Steve Ligertwood Dr. Roderick Tukker Dr. David Wilton

Perioperative Management of the Anticoagulated Patient

Getting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis

High Alert Medications: Reducing Patient Harm. Tennessee Center for Patient Safety Regional Meetings 2017 Brian D. Esters, PharmD, CPPS

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN

Family Medicine Clinical Pharmacy Forum Vol. 4, Issue 5 (September/October 2008)

PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT

Prevention and management of venous thromboembolism M. AAPRO

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community

ADMINISTRATIVE CLINICAL Page 1 of 6

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)

Challenges in Anticoagulation and Thromboembolism

Heparin-Induced Thrombocytopenia (HIT)

New Age Anticoagulants: Bleeding Considerations

Aspirin as Venous Thromboprophylaxis

Epidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005

A Brief History of the World of Anticoagulation

Primary Stroke Center Quality & Performance Measures

Misunderstandings of Venous thromboembolism prophylaxis

Venous Thromboembolism Prophylaxis: Checked!

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL

Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1

Change from lovenox to pradaxa

Acute and long-term treatment of PE. Cecilia Becattini University of Perugia

2/9/2016. A Multi-Disciplinary Program to Decrease the Rate of Preventable Harm from Medication Events. Objectives:

Venous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017

Utilizing Automated Adverse Event Detection

EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI

Updates in Diagnosis & Management of VTE

Pharmacy Leadership, Touching all the Bases

Anticoagulant Therapy During Pregnancy

Challenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest

AUDIT REPORT. Salisbury District Hospital. Odstock Road. Salisbury. Wiltshire. February Page 1 of 20

Using an anti-xa level nomogram to adjust intravenous unfractionated heparin infusion for arrhythmia in pregnancy

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018

VENOUS THROMBOEMBOLISM (VTE) PREVENTION MEDICAL PROVIDER EDUCATION JUNE 2017

The spectrum of clinical outcome of PE

Perioperative VTE Prophylaxis

BACKGROUND AND OBJECTIVE: Hospital-acquired venous thromboembolic events

INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY

ADULT TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) TELEMETRY BED TRANSFER ORDERS 1 of 4

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

What s new with DOACs? Defining place in therapy for edoxaban &

Optimizing Anticoagulation Care Series:

Reducing the Use of Reversal Agents in a Community Hospital

Factor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)

NICE Guidance: Venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital 1

Hot Topics: Transitions of Care

Drug Class Monograph

Slide 1: Perioperative Management of Anticoagulation

Chapter 1 The Reversing Agents

Anticoagulation Therapy in LTC

Pain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN

DVT - initial management NSCCG

The legally binding text is the original French version. Opinion 15 May 2013

Admit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests. CBC, Electrolytes, Urea, Creatinine, Glucose, INR, PTT, Urinalysis

Update on the Management of Cancer Associated VTE

Do s and Don t of DOACs DISCLOSURE

Anticoagulation therapy : improving processes. Hilary Merrett and Fiona Gale, CHKS 18 th October 2010

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

Prevention of Venous Thromboembolism

Anticoagulation for prevention of venous thromboembolism

Clinical Practice Committee Anticoagulation Bridging Document

What You Should Know

New Antithrombotic Agents

(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris

DOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD

Are guidelines for anticoagulation useful in cancer patients?

AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS

Managing Bleeding in the Patient on DOACs

A Prospective, Controlled Trial of a Pharmacy- Driven Alert System to Increase Thromboprophylaxis rates in Medical Inpatients

New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)

Leveraging Rules and Alerts to Improve Patient Safety and Clinical Pharmacy Services

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:

convey the clinical quality measure's title, number, owner/developer and contact

Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks

Transcription:

Ensuring Safety of Anticoagulation Therapy Abha Agrawal, MD, FACP Chief Medical Officer Kings County Hospital Clinical Associate Dean SUNY Downstate College of Medicine Brooklyn, NY NYACP Webinar April 29 2011

CME Disclosure Abha Agrawal has no relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Kings County Hospital Center 650-bed academic tertiary hospital Level-1 1 Trauma Center 26,000 discharges 750,000 clinic visits 130,000 ED visits

NYC HHC Largest municipal health system in the country 11 acute care hospitals >100 diagnostic and treatment centers 7,700 beds 23,000 deliveries 227,000 admissions

Agenda Risks of anticoagulants Safety strategies Using health IT to improve anticoagulation safety Case study 1: Electronic anticoagulation protocol Case study 2: Root cause analysis of a medication error

Balancing the Risk Bleeding Thromboembolism

Problem PE remains the commonest preventable cause of hospital deaths. Many at-risk patients don t t receive VTE prophylaxis (Lancet Jun 2008 ENDORSE study): TOTAL: >68,000 patients Surgical 65% at-risk,, medical 42% at-risk Of at-risk patients Surgical 59% received recommended prophylaxis Medical 40% received recommended prophylaxis

VTE Occurs Despite Prophylaxis NEJM PROTECT Apr 7 2011 study Critically ill patients 3764 patients 1873 in dalteparin arm 5.1% had DVT despite prophylaxis 1.3% had PE 1873 in UFH arm 5.8% had DVT despite prophylaxis 2.3% had PE

Risk of Anticoagulants Disturbing Numbers Ahead!!

Medicare OIG study Nov 2010 780 Medicare beneficiaries discharged in Oct 2008 13.5 %: adverse events Additional 13.5% - temporary harm 44% preventable 1.5% - contributed to their deaths = 15,000 Medicare beneficiaries in a month (based on ~ 1 million in a month)

OIG Medicare Study Infections 15% Medications 31% Surgery / Procedures 26% Ongoing Pt Care 28%

Medicare OIG Study (Contd.) Medication events 31% = 40 Excessive bleeding - 12 Delirium or change in mental status - 7 Hypoglycemic event 6 Acute renal insufficiency 4 Severe hypotension 4 Respiratory complications 4 Severe allergic reactions - 3

OIG Medicare Study 12 deaths 7 Meds Related 5 ACs Other 5 2 blood stream infection 2 aspiration 1 VAP Other 2 Hypoglycemic episodes

Drivers

Drivers ISMP: 3 of 14 high alert meds are anticoagulants AHRQ 2011: AC safety as 1 of 11 high impact interventions Leapfrog safety objective #18: march 2006 NPSG: 2011: goal: #3 AC included in IHI 5 million lives campaign

Joint Commission Sentinel Events Sentinel Events Alert #41: 2008 Anticoagulants: One of the 5 drugs associated with patient safety incidents. MEDMARX database: 2001-2006 2006 59,316 anticoagulants related errors reported 60% reached the patient 3% led to harm or death Performance error (e.g. administration is the most common cause of error).

Risk of Anticoagulants Hemorrhagic complications IV UFH: <3% Risk increases with increased dosage and age >70 years LMWH: less major bleeding than UFH Thrombolytic therapy increases the risk of major bleeding 1.5 3X in patients receiving AC therapy Chest 2008: ACCP Guidelines

Why anticoagulants are high risk meds? Narrow therapeutic range Interaction with many common foods and medications Need frequent and timely lab monitoring Special issues exist in the elderly, including bleeding complications associated with falls Special risks in neonates

Why anticoagulants are high risk meds? (contd.) Lack of standardization for the naming, labeling and packaging of anticoagulants creates confusion. Potentially confusing dosing regimens, newer agents. Special risk during transfers and hand- offs.

Anticoagulants: Risk Points Lack of critical patient information Ht, wt, allergies missing or dated Lab values PT/PTT/INR missing or didn t see Baseline monitoring Concomitant use of other anticoagulants Renal impairment Transfers and hand-offs

Agenda Risks of anticoagulants Safety strategies Using health IT to improve anticoagulation safety Case study 1: Electronic anticoagulation protocol Case study 2: Root cause analysis of a medication error

Steps in Medication Process Prescribing 39% CPOE / Decision Support Transcription 12% Dispensing 11% Robots / Pyxis machines Administration 38% Bar-coded med admin Bates, BMJ, 2000 Leape et al. JAMA. 1995

What s s in a name? Error Adverse Event Bates DW et al. J Gen Intern Med. 1993

Medication Errors Sharp End Errors = Active Errors Blunt End Errors = Latent Errors Reason, James. Human Error. Cambridge University Press, 1990

Reason s s Swiss Cheese Model

Human versus Systems: Complexity

I don t t want to make the wrong mistake. Yogi Berra

Agenda Risks of anticoagulants Safety strategies Using health IT to improve anticoagulation safety Case study 1: Electronic anticoagulation protocol Case study 2: Root cause analysis of a medication error

Case Study 1: Electronic Acute Anticoagulation Therapy Protocol Covers UFH, LMWH and Warfarin Integrated into hospital-wide EHR and CPOE Integrated into bar-cod medication administration module for nurses Used in ED and Inpatient all services Hirsh J et al. Chest June 2008. Antithrombotic and thrombolytic therapy. ACCP evidence-based clinical practice guidelines

Electronic AC Therapy Protocol Methodology Corporate-wide AC Committee Jan 2007 Representation from multiple hospitals Included MD, RN, Lab, Pharmacy, IT, Project Management Reviewed literature, recommended dosing guidelines, defined design specifications and workflow integration, beta testing. Nov 2007: pilot at Bellevue Hospital Next ~ 18 months: corporate-wide rollout

Electronic AC Therapy Protocol Objectives Improving adherence to evidence-based AC guidelines Reducing variations in dosing protocols across HHC Improving safety by providing point-of of-care decision support during ordering process Improving communication between physicians, nurses, and pharmacists

Features Dosing recommendations for UFH, LMWH, Warfarin based on evidence-based guidelines Automated ordering of corollary lab orders such as CBC, aptt and platelet count with medication ordering Trend report, built in the order set, summarizing historic anticoagulation medication and pertinent lab ordering from the last 10 calendar days available from the order entry screen

Point-of of-care Decision Support No weight alert Weight consideration alert if >72 hr old Baseline lab warning Platelet warning <100 k or >50% drop Creatinine clearance calculation and warning Embedded mandatory HIT question

Anticoagulation Order Set

UFH Order Set

Heparin bolus order

Rx / Lab Report

Corollary Orders with Heparin

UFH Adjustment Dose

Decision Support Features

Enoxaparin

Enoxaparin

Fondaparinux order set

Fondaparinux

Fondaparinux To order fondaparinux, patient must have a cr clearance of >= 30 ml/min, determined from the most recent weight and serum creatinine results. If any of these three are missing or not recent, enter or order the appropriate values.

Coumadin

Warfarin Nomogram

Warfarin Nomogram: : Patient s s INR is 1.2

Select therapy day

Day 5 of the Nomogram

Day 6 of the Nomogram

Case Study 2: Medication Error 74 year old man with multisystem illness in MICU develops PE. Started on heparin infusion develops Heparin- induced thrombocytopenia Prescribed correct weight-based dose of Argatroban. Pharmacist dispenses correct IV mixed bag Nurse mistakenly infuses 20X greater dose of the medication. Patient dies of bleeding complications within 12 hours.

Argatroban Order

Label on the IV bag

Kǘbler-Ross Stages: Medication Safety I - Denial II - Anger The data are wrong The data are right, but it s not a problem III - Bargaining The data are right; it s a problem, but it s not my problem IV - Depression It s my problem, but there is nothing I can do about it V - Acceptance I accept the burden of improvement Adapted from Donald Berwick, MD, IHI 2004 Frontiers of Healthcare conference

Knowing is not enough; we must apply. Willing is not enough; we must do. Johann Wolfgang von Goethe.